Daniel A. Laheru

Johns Hopkins University School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Supplementary Figure 5. Best radiographic response to relatlimab and nivolumab in patients with microsatellite stable colorectal cancer stratified by pre-treatment cytotoxic T cell (A) and Treg (B) density.

Year:

2025

Supplementary Figure 5. Best radiographic response to relatlimab and nivolumab in patients with microsatellite stable colorectal cancer stratified by pre-treatment cytotoxic T cell (A) and Treg (B) density.

Year:

2025

Purpose: Combined inhibition of lymphocyte-activation gene 3 (LAG-3) and PD-1 improves outcomes in patients with melanoma. Increased LAG-3 expression in colorectal cancer correlates with reduced survival. Higher mucin and PD-L1 expression in the mismatch repair–proficient (pMMR) colorectal cancer tumor microenvironment was associated with increased LAG-3 and retrospectively with prolonged progression-free survival upon PD-1 blockade. This led to the hypothesis that LAG-3/PD-1 inhibition would improve clinical outcomes in this pMMR colorectal cancer subset. Patients and Methods: NCT03642067 was a phase II study evaluating the combination of relatlimab (LAG-3 inhibitor) and nivolumab (PD-1 inhibitor) in patients with previously treated metastatic pMMR colorectal cancer. Patients were enrolled into one of three cohorts: A, mucin/PD-L1–high; B, mucin/PD-L1–low; or C, mucin/PD-L1 unselected. The primary endpoint for each cohort was the objective response rate. Results: We enrolled 59 evaluable patients; best treatment responses were partial response (3), stable disease (6), and progressive disease (50). Response rates did not differ significantly between cohorts. Subgroup analyses demonstrated that two of five patients with lung-only metastases had a partial response. Comparison of liver and lung metastases identified higher baseline dendritic cell densities in lung lesions. Nivolumab/relatlimab resulted in increased intratumoral cytotoxic T cells. Lower baseline intratumoral regulatory T cells and ADAM10 + cancer cells correlated with clinical response. Conclusions: This investigation did not reach its primary endpoint for any of the three treatment cohorts but does provide critical insight into the effects of combining nivolumab/relatlimab on the colorectal cancer tumor microenvironment and identifies subgroups that may derive greater benefit from this combination.

Year:

2025

Purpose: Borderline resectable pancreatic ductal adenocarcinoma (PDAC) is treated with perioperative chemotherapy and surgical resection with or without stereotactic body radiotherapy (SBRT), but long-term survival is rare. GVAX is a GM-CSF–secreting vaccine that activates T-cell immunity against tumor-associated antigens. This multicenter phase II clinical trial evaluated the safety and immune effects of GVAX/cyclophosphamide/nivolumab and SBRT on the PDAC tumor microenvironment (TME). Patients and Methods: Patients received neoadjuvant mFOLFIRINOX or gemcitabine/nab-paclitaxel if intolerant to mFOLFIRINOX followed by combination immunotherapy and SBRT before surgical resection. The primary endpoint was CD8 + T-cell density in surgical specimens compared with in historic control samples treated with neoadjuvant mFOLFIRINOX and SBRT only. Pathologic response rate, overall survival, and exploratory immune evaluation of the TME are also reported. Results: Thirty-one patients were enrolled from January 2018 to July 2021. Eighteen patients received at least one dose of combined immunotherapy. Fourteen patients underwent definitive surgical resection, and one pathologic complete response was observed. At a median follow-up of 19.5 months, the median overall survival was 20.4 months (95% confidence interval, 18.2–not achieved). There was no difference in the mean CD8 T-cell density between study patients and historic control patients. Nonsignificant increases in the abundance score for specific immune cell subsets were observed in responders as compared with nonresponders. Conclusions: The addition of combined immunotherapy and SBRT was safe and feasible in this patient population. No difference was observed in the mean CD8 T-cell density between study patients and historic controls. These findings support the need for better characterization of how neoadjuvant immunotherapy may shift the phenotype of the PDAC TME.

Year:

2025

Background: We previously reported increased M1/M2 ratio and decreased PDL1+ M2-like tumor associated macrophages (TAM) was associated with longer survival in pancreas adenocarcinoma (PDA). We hypothesized targeting M2-like macrophages, regulated by the colony stimulating factor-1 (CSF1) pathway, would be safe and induce an intratumoral immune response. We tested perioperative combination immunotherapy (CI): GVAX/cyclophosphamide (CY), pembrolizumab (Pem), and CSF1 receptor blockade (IMC-CS4) in patients with PDA. Methods: Patients received two neoadjuvant cycles of CI followed by surgery and 4 adjuvant cycles of CI. Subsequently, they received booster Pem every 3 weeks and GVAX/CY every 6 months, for up to one year. Co-primary endpoints were safety and immune response in paired biopsies. Results: Nine patients were enrolled and treated. We observed two immune related grade 3/4 AEs (diarrhea and rash). Comparison of paired biopsies showed 5 of 8 evaluable patients met the immunologic endpoint with >80% increase in CD8+ T cells. The increase was at least 1.8 times the baseline median absolute deviation. Conclusion: CI had a manageable safety profile and led to increased intratumoral cytotoxic effector T cells.

Year:

2024

Ten percent of pancreatic neuroendocrine tumors (pNET) are related to inherited syndromes ( MEN1 , MEN4 , VHL , NF1 , and TSC ). Growing evidence suggests that clinically sporadic pNETs can also harbor germline pathogenic variants. In this study, we report the prevalence of pathologic/likely pathologic (P/LP) germline variants in a high-risk cohort and an unselected cohort. We collected clinical data of patients with pNETs seen at MD Anderson Cancer Center and Johns Hopkins Hospital. The high-risk cohort included ( n = 132) patients seen at MD Anderson Cancer Center who underwent germline testing for high-risk criteria (early onset, personal or family history of cancer, and syndromic features) between 2013 and 2019. The unselected cohort included ( n = 106) patients seen at Johns Hopkins Hospital who underwent germline testing following their diagnosis of pNETs between 2020 and 2022. In the high-risk cohort ( n = 132), 33% ( n = 44) had P/LP variants. The majority of the patients had P/LP variants in MEN1 56% ( n = 25), followed by DNA repair pathways 18% ( n = 8), and 7% ( n = 3) in MSH2 (Lynch syndrome). Patients with P/LP were younger (45 vs. 50 years; P = 0.002). In the unselected cohort ( n = 106), 21% ( n = 22) had P/LP. The majority were noted in DNA repair pathways 40% ( n = 9) and MEN1 36% ( n = 8). Multifocal tumors correlated with the presence of P/LP ( P = 0.0035). MEN1 germline P/LP variants correlated with younger age (40 vs. 56 years; P = 0.0012), presence of multifocal tumors ( P P = 0.0078). P/LP variants are prevalent in patients with clinically sporadic pNET irrespective of high-risk features. The findings support upfront universal germline testing in all patients with pNET. Prevention Relevance: Here, we present germline data from the largest reported cohort of patients with pNET ( n = 238), comprising both a high-risk cohort and an unselected cohort. In both cohorts, we identify a high number of P/LPs, including those in the DNA repair pathway. Our findings support universal germline testing in patients with pNET.

Year:

2024

Ten percent of pancreatic neuroendocrine tumors (pNET) are related to inherited syndromes ( MEN1 , MEN4 , VHL , NF1 , and TSC ). Growing evidence suggests that clinically sporadic pNETs can also harbor germline pathogenic variants. In this study, we report the prevalence of pathologic/likely pathologic (P/LP) germline variants in a high-risk cohort and an unselected cohort. We collected clinical data of patients with pNETs seen at MD Anderson Cancer Center and Johns Hopkins Hospital. The high-risk cohort included ( n = 132) patients seen at MD Anderson Cancer Center who underwent germline testing for high-risk criteria (early onset, personal or family history of cancer, and syndromic features) between 2013 and 2019. The unselected cohort included ( n = 106) patients seen at Johns Hopkins Hospital who underwent germline testing following their diagnosis of pNETs between 2020 and 2022. In the high-risk cohort ( n = 132), 33% ( n = 44) had P/LP variants. The majority of the patients had P/LP variants in MEN1 56% ( n = 25), followed by DNA repair pathways 18% ( n = 8), and 7% ( n = 3) in MSH2 (Lynch syndrome). Patients with P/LP were younger (45 vs. 50 years; P = 0.002). In the unselected cohort ( n = 106), 21% ( n = 22) had P/LP. The majority were noted in DNA repair pathways 40% ( n = 9) and MEN1 36% ( n = 8). Multifocal tumors correlated with the presence of P/LP ( P = 0.0035). MEN1 germline P/LP variants correlated with younger age (40 vs. 56 years; P = 0.0012), presence of multifocal tumors ( P P = 0.0078). P/LP variants are prevalent in patients with clinically sporadic pNET irrespective of high-risk features. The findings support upfront universal germline testing in all patients with pNET. Prevention Relevance: Here, we present germline data from the largest reported cohort of patients with pNET ( n = 238), comprising both a high-risk cohort and an unselected cohort. In both cohorts, we identify a high number of P/LPs, including those in the DNA repair pathway. Our findings support universal germline testing in patients with pNET.

Year:

2024

Figure S4 shows the raw multiplex serum cytokine analysis data from Figure 4, and the antibody list and the gating strategy for the CyTOF analysis, all performed on the peripheral blood samples.

Year:

2024

Figure S4 shows the raw multiplex serum cytokine analysis data from Figure 4, and the antibody list and the gating strategy for the CyTOF analysis, all performed on the peripheral blood samples.

Year:

2024

Purpose: CD40 activation is a novel clinical opportunity for cancer immunotherapy. Despite numerous active clinical trials with agonistic CD40 monoclonal antibodies (mAb), biological effects and treatment-related modulation of the tumor microenvironment (TME) remain poorly understood. Patients and Methods: Here, we performed a neoadjuvant clinical trial of agonistic CD40 mAb (selicrelumab) administered intravenously with or without chemotherapy to 16 patients with resectable pancreatic ductal adenocarcinoma (PDAC) before surgery followed by adjuvant chemotherapy and CD40 mAb. Results: The toxicity profile was acceptable, and overall survival was 23.4 months (95% confidence interval, 18.0–28.8 months). Based on a novel multiplexed immunohistochemistry platform, we report evidence that neoadjuvant selicrelumab leads to major differences in the TME compared with resection specimens from treatment-naïve PDAC patients or patients given neoadjuvant chemotherapy/chemoradiotherapy only. For selicrelumab-treated tumors, 82% were T-cell enriched, compared with 37% of untreated tumors ( P = 0.004) and 23% of chemotherapy/chemoradiation-treated tumors ( P = 0.012). T cells in both the TME and circulation were more active and proliferative after selicrelumab. Tumor fibrosis was reduced, M2-like tumor-associated macrophages were fewer, and intratumoral dendritic cells were more mature. Inflammatory cytokines/sec CXCL10 and CCL22 increased systemically after selicrelumab. Conclusions: This unparalleled examination of CD40 mAb therapeutic mechanisms in patients provides insights for design of subsequent clinical trials targeting CD40 in cancer.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (22)

Robert H. Vonderheide

University of Pennsylvania

UNITED STATES
View details

Ross Donehower

Professor

Johns Hopkins University

UNITED STATES
View details

Eric S Christenson

Assistant Professor of Oncology

Johns Hopkins University School of Medicine

UNITED STATES
View details

Michael Pishvaian

Associate Professor

Johns Hopkins University

UNITED STATES
View details

franck housseau

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Parul Agarwal

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Hao Wang

Johns Hopkins University

UNITED STATES
View details

Florencia McAllister

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alison Klein

Professor

-

UNITED STATES
View details

David Bajor

Case Western Reserve University

UNITED STATES
View details

E. Gabriela Chiorean

Professor of Medicine

University of Washington

UNITED STATES
View details

Mark Yarchoan

Johns Hopkins University

UNITED STATES
View details

Matthew H. G. Katz

Professor

-

UNITED STATES
View details

Ana De Jesus-Acosta

Johns Hopkins University

UNITED STATES
View details

Hanfei Qi

Johns Hopkins University

UNITED STATES
View details

Won Jin Ho

Johns Hopkins University School of Medicine

UNITED STATES
View details

Michael P. Kim

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jessica Maxwell

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elizabeth M. Jaffee

Johns Hopkins University School of Medicine

UNITED STATES
View details

Jin He

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Richard A. Burkhart

Johns Hopkins University School of Medicine

UNITED STATES
View details

Drew Pardoll

Professor

Johns Hopkins University

UNITED STATES
View details